MLXIPL and Hepatic steatosis: The above results, taken together, provide the first evidence that targeting hepatic PDKs with the PDK inhibitor, PS10, mitigates hepatic glucose production and attenuates ChREBP-mediated lipogenesis, resulting in markedly reduced hepatic steatosis.